Tribenoside
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Tribenoside is an anti-inflammatory agent that reduces vascular permeability and causes vasoconstriction to treat internal and external hemorrhoids.
- Generic Name
- Tribenoside
- DrugBank Accession Number
- DB13227
- Background
Anti-inflammatory agent used in edema of extremities, varicose veins & phlebitis.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 478.585
Monoisotopic: 478.235538815 - Chemical Formula
- C29H34O6
- Synonyms
- TBGF
- Tribenoside
- Tribenosido
- Tribenosidum
- External IDs
- 21401-BA
- Ba 21401
- BG-356
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Hemorrhoids Combination Product in combination with: Lidocaine (DB00281) •••••••••••• •••••• ••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image PROCTO - GLYVENOL® SUPOSITORIOS Tribenoside (400 mg) + Lidocaine (40 mg) Suppository Rectal DELPHARM HUNINGUE S.A.S 2006-11-10 Not applicable Colombia PROCTO GLYVENOL %5 +%2 KREM, 30 G Tribenoside (5 %) + Lidocaine (2 %) Cream Rectal RECORDATİ İLAÇ SAN. VE TİC. A.Ş. 2011-05-18 Not applicable Turkey PROCTO-GLYVENOL %20 +%2 SUPOZITUAR, 10 ADET Tribenoside (20 %) + Lidocaine (2 %) Suppository Rectal RECORDATİ İLAÇ SAN. VE TİC. A.Ş. 2011-05-18 Not applicable Turkey PROCTO-GLYVENOL CREMA Tribenoside (5 g) + Lidocaine hydrochloride (2.12 g) Cream Rectal; Topical GSK CONSUMER HEALTHCARE S.A. 2006-11-10 2023-09-14 Colombia
Categories
- ATC Codes
- C05AX05 — Tribenoside
- C05AX — Other agents for treatment of hemorrhoids and anal fissures for topical use
- C05A — AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
- C05 — VASOPROTECTIVES
- C — CARDIOVASCULAR SYSTEM
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- O-glycosyl compounds
- Alternative Parents
- Benzylethers / Monosaccharides / Tetrahydrofurans / Secondary alcohols / Oxacyclic compounds / Dialkyl ethers / Acetals / Hydrocarbon derivatives
- Substituents
- Acetal / Alcohol / Aromatic heteromonocyclic compound / Benzenoid / Benzylether / Dialkyl ether / Ether / Hydrocarbon derivative / Monocyclic benzene moiety / Monosaccharide
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z7N0Y673NU
- CAS number
- 10310-32-4
- InChI Key
- ULLNJSBQMBKOJH-VIVFLBMVSA-N
- InChI
- InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25-,26-,27-,28-,29?/m1/s1
- IUPAC Name
- (3R,4R,5R)-4-(benzyloxy)-5-[(1R)-1,2-bis(benzyloxy)ethyl]-2-ethoxyoxolan-3-ol
- SMILES
- CCOC1O[C@H]([C@@H](COCC2=CC=CC=C2)OCC2=CC=CC=C2)[C@H](OCC2=CC=CC=C2)[C@H]1O
References
- General References
- External Links
- ChemSpider
- 169970
- 38557
- ChEBI
- 91780
- ChEMBL
- CHEMBL3301681
- Wikipedia
- Tribenoside
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Completed Screening Colonic Adenomatous Polyps / Colorectal Cancer / Colorectal Neoplasms 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 400.000 mg Capsule, liquid filled Oral 400 mg Suppository Rectal Cream Rectal Cream Rectal; Topical Capsule Oral 400 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00325 mg/mL ALOGPS logP 4.13 ALOGPS logP 5.17 Chemaxon logS -5.2 ALOGPS pKa (Strongest Acidic) 12.36 Chemaxon pKa (Strongest Basic) -3.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 66.38 Å2 Chemaxon Rotatable Bond Count 13 Chemaxon Refractivity 133.51 m3·mol-1 Chemaxon Polarizability 52.51 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00b9-1117900000-fd47ef2f7dfeba13f36c Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00or-0398100000-63de29d311ac558d32f1 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00bc-3309600000-d207c4fd62ce14b4433b Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00or-3069000000-c1ace2d19f91e46e2e21 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-01sl-3978300000-b9e05b4d8be1a3ea3990 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0007-9131100000-931c4f176aba0c5de660 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 200.99489 predictedDeepCCS 1.0 (2019) [M+H]+ 203.39046 predictedDeepCCS 1.0 (2019) [M+Na]+ 209.303 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:38 / Updated at June 05, 2021 09:13